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Abstract
Background. Both the phenotypic alterations of parathy-
roid(PT)cells,e.g.down-regulationofthecalcium-sensing
receptor, and the increase of the PT cell number in nodu-
lar hyperplasia are the main causes of refractory secondary
hyperparathyroidism. It is of great importance to prevent
PT growth in an early stage.
Methods. To examine a more effective method of calcitriol
therapy for the prevention of PT hyperplasia, we random-
ized haemodialysis patients with mild hyperparathyroidism
toreceiveeitherdailyorallyadministeredcalcitriol(n=33)
orintravenouscalcitriol(n=27)overa12-monthstudype-
riod.Calcitriolwasmodulatedsoastokeeptheserumintact
PTH level between 100 and 150 pg/ml.
Results. Both groups showed similar reductions of the
serumPTHlevelandsimilarincreasesinserumcalcium.In
bothgroups,therewerenosignificantchangesintheserum
phosphate level. Long-term daily oral calcitriol therapy
failed to prevent the increase of both maximum PT volume
and total volume, as assessed by ultrasonography; however,
intravenous calcitriol therapy successfully suppressed this
progression. In the daily, oral group, both the bone-specific
alkaline phosphatase (BAP) and the N-telopeptide cross-
linked of type I collagen (NTX) significantly decreased,
which was probably due to the PTH suppression. However,
these bone metabolism markers remained stable in the in-
travenous group. The total dosage of calcitriol during the
study was comparable in both groups.
Conclusions.Thesedataindicatethatintravenouscalcitriol
therapy in an early stage of secondary hyperparathyroidism
is necessary to prevent PT growth and to keep a good con-
dition of bone metabolism.
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Introduction
Secondary hyperparathyroidism is a serious complication
inpatientswithrenalfailure.Ithasbeenreportedthatitsae-
tiologicalfactorsincludeactivevitaminD(VD)deficiency,
hypocalcaemia and an excessive level of phosphate (Pi). To
treat this disorder, VD supplementation and the adminis-
tration of a Pi binder have been performed. However, the
correction of these serological abnormalities does not in-
hibit the excessive secretion of parathyroid hormone (PTH)
in some patients. Concerning parathyroid (PT) hyperplasia
in humans, diffuse hyperplasia may histologically deterio-
ratetonodularhyperplasia[1].Inthelatter,quantitative(an
increase in the cell count) and qualitative [a decrease in the
expressions of vitamin D receptors (VDR) and calcium-
sensing receptors (CaSR)] changes are marked, which
may contribute to the medical therapy-refractory condition
[2,3,4,5].Thereisasecondaryhyperparathyroidism-related
increaseinthePTHlevelwhenthevalueofcreatinineclear-
ance becomes 30 ml/min or less. Usually, the PTH level is
controlled with oral VD preparations in the early stage.
Even after dialysis is started, therapy with oral VD prepa-
rations is continued in many Japanese patients with an in-
tact PTH level of ∼300 pg/ml or less, although there are
slight differences among hospitals. When PTH control is
difficult, this therapy is switched to intravenous (IV) VD
therapy. However, the control of serum calcium (Ca) and
Pi levels gradually becomes difficult, making the continu-
ation of intravenous VD therapy difficult. On echography,
PT enlargement suggests nodular hyperplasia, often requir-
ing parathyroidectomy and percutaneous ethanol injection
therapy. Briefly, it is important to inhibit deterioration to
nodular hyperplasia for long-term control of secondary
hyperparathyroidism.
With respect to VD administration methods, previous
clinical studies compared oral-pulse/daily-oral treatment
with IV treatment [6,7,8,9,10,11,12]. However, a consen-
sus regarding VD-related changes in the PT volume has not
been reached. Fukagawa et al. [13,14] reported a decrease
in the PT volume on echography after VD pulse therapy
for 12 weeks. Quarles et al. [6] indicated that there were
no changes in the PT volume on echography nor magnetic
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resonance imaging (MRI) after intravenous VD therapy.
In the former study, the PT volume was relatively small;
therefore, intravenous VD therapy in the phase of diffuse
hyperplasia, with a small PT volume, may inhibit PT en-
largement.Inanexperiment using5/6nephrectomized rats,
bolus VD therapy immediately after renal failure induction
inhibited PT enlargement [15,16].
Considering that conventional daily oral (DO) VD ther-
apy does not inhibit PT enlargement, we conducted a
prospective randomized study to investigate the inhibitory
effects of intravenous VD therapy in the initial phase of
secondary hyperparathyroidism, in which PT enlargement
begins, on PT enlargement.
Methods
Patient selection
A total of 77 patients were recruited into the study from 23
haemodialysis units from January 2004 to November 2005.
Entry criteria included a serum intact PTH concentration
between 100 pg/ml and 300 pg/ml, and three times weekly
haemodialysis for >6 months. Patients were excluded
for the following reasons: prior treatment with calcitriol
oral pulse or IV calcitriol, corrected calcium exceeding
10.5 mg/dl, serum phosphorus >6.5 mg/dl or serum alka-
line phosphatase <115 U/l.
Study protocol
The study protocol consisted of an initial 2-week control
periodanda12-monthtreatmentperiod.Allpatientssigned
informed consent forms prior to entering the study. During
the control period, all vitamin D oral drugs and injections
were discontinued for 2 weeks. A total of 77 patients were
initially enrolled. Of these patients, five failed to complete
the entry criteria. Seventy-two patients were randomized to
receive one of the following two protocols: daily orally cal-
citriol (DO group) or IV calcitriol (IV group, Rocaltrol
R 
Injection:KIRINBreweryLtd.,Tokyo,Japan).IVcalcitriol
wasadministeredthreetimesweeklyattheendofeachdial-
ysistreatmentprocedure.Theplanneddurationoftreatment
was 12 months. A restricted randomization technique was
employed to assign these study participants to the treat-
ment groups. At registration, we employed the minimiza-
tion method and assigned the subjects to two groups so
that there were no differences in gender nor the presence
or absence of previous VD therapy. Using this method,
72 patients were randomized to the DO (N = 35) and IV
(N = 37) group.
Calcitriol was started at an initial dose of 0.25 µgi n
the DO group and 0.5 µg in the IV group, respectively.
The dose of calcitriol was increased or decreased by
0.5 µg/week to maintain the serum PTH level between 100
pg/ml and 150 pg/ml. Upward adjustments of calcitriol
doses were not performed if the serum calcium and phos-
phorus levels exceeded 10.5 mg/dl and 5.5mg/dl, respec-
tively. Severe hypercalcaemia (serum calcium >11.5 mg/dl
for 2 months), a low PTH level (intact PTH <100 pg/ml
for 2 months) and low bone metabolism markers (when all
bone metabolism markers were below the lower limits of
the normal ranges for 2 months) were treated by discontin-
uing calcitriol. If the cessation of calcitriol was necessary,
it was restarted with reference to the dose before discon-
tinuation. As a rule, sevelamer hydrochloride was used as
a phosphate-adsorbing agent to maintain serum phosphate
levelsrangingfrom3.5to5.5mg/dl.However,whencontrol
with sevelamer hydrochloride alone was difficult, the agent
was combined with other phosphate-binding agents (cal-
cium carbonate, etc.). As a rule, the dialysate Ca level was
established as 3.0 mEq/l. Combination therapy with VD
preparations other than the test agent, ipriflavone, bispho-
sphonate or aluminium preparations was contraindicated.
Patients in whom a corrected Ca level of >10.5 mg/dl, a
phosphate level of >6 mg/dl or a Ca/phosphate product of
>65 mg2/dl2 had persisted for 4 weeks were excluded from
this study.
Ofthe72patients whoentered thetreatmentprotocol, 60
completed the planned 12 months. Two subjects requested
to end the involvement for unspecified personal reasons;
one patient was removed from the study because of uncon-
trolledhypercalcaemia;threesubjectswereexcludeddueto
the deterioration of other diseases. The remaining patients
were excluded from this study due to a lack of data.
Biochemical parameters
During the study protocol, serum-corrected calcium and
phosphorus were measured weekly. Serum intact PTH
and alkaline phosphatase were determined monthly, and
both bone-specific alkaline phosphatase (BAP) and N-
telopeptide cross-linked of type 1 collagen (NTX) were
measured at the start and in the 3rd, 6th and 12th month.
Serum FGF23 levels were assessed at the outset of this
study. Serum calcium and phosphorus were measured by
eachdialysisunit.SerumBAPwasmeasuredbyOsteolinks
BAP (Quidel Corpora Serum, San Diego, CA, USA). In-
tact PTH was measured by the Allegro Intact PTH kit;
Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA. Serum osteocalcin (OC) was measured by Osteo-
calcin Test Kokusai-F (International Reagents Corpora-
tion, Tokyo, Japan). Concerning OC, the sale of a mea-
suring kit was discontinued during the study period, and
this parameter was excluded. Serum NTX was measured
by OSTEOMARK
R  NTx serum (Inverness Medical Pro-
fessional Diagnostics, Princeton, NJ, USA). Serum FGF23
was measured by the FGF-23 ELISA Kit (KAINOS LAB-
ORATORIES, INC., Tokyo, Japan).
Parathyroid gland imaging
At the start of the study protocol and after 12 months of
therapy, patients in both treatment groups were scheduled
for imaging studies to assess the PT gland size. Of the 60
patients, pre- and post-imaging studies were successfully
performed in 58 patients. The PT gland size was assessed
by ultrasonography before and after the treatment. Most
of measurements of the PT gland size were made by the
authors (M. Taniguchi and M. Tokumoto). Eleven of 58
patients were assessed by the medical laboratory techni-
cian in a distant institution. The measuring methods were3664 M. Taniguchi et al.
Table 1. Clinical features
OD group IV group P-value
N 33 27 –
Age (years) 66 ± 10 59 ± 12 0.235
Gender (male/female) 19/14 17/10 0.438
Primary disease (DM/non-DM) 5/28 2/25 0.309
Haemodialysis duration (years) 7.5 ± 5.9 7.1 ± 6.7 0.867
History of vitamin D therapy (yes/no) 25/8 22/5 0.583
Dialysate calcium concentration 2/31 7/20 0.065
(2.5/3.0 mEq/l)
Biochemical parameters at entry
Corrected calcium (mg/dl) 9.2 ± 0.7 9.3 ± 0.7 0.915
Phosphate (mg/dl) 4.6 ± 1.0 5.0 ± 1.0 0.126
Alkaline phosphatase (U/l) 236 ± 94 227 ± 65 0.101
Intact PTH (pg/ml) 230 ± 100 282 ± 167 0.209
BAP (U/l) 30 ± 13 26 ± 13 0.154
OC (ng/ml) 23 ± 13 19 ± 12 0.265
NTX (nmol/l) 137 ± 87 146 ± 92 0.818
Parathyroid gland volume at entry
Maximum gland (mm3)4 9 ± 73 96 ± 215 0.298
Total glands (mm3)6 5 ± 108 150 ± 292 0.169
Data are expressed as mean ± SD.
n, number of specimens; DM, diabetes mellitus; PTH, parathyroid hor-
mone; BAP, bone-specific alkaline phosphatase; OC, osteocalcin; NTX,
N-telopeptide cross-linked of type 1 collagen.
standardized as follows. The visualized glands were mea-
suredintheanterio-posterior(a),transverse(b)andlongitu-
dinal(c)dimensionstocalculatePTvolumes.Wemeasured
the PT size using the following formula:
Estimated PT volume = π/6 × a × b × c.
Statistical analysis
Data are expressed as the mean ± SD. All statistical anal-
yses were conducted using the DOCTOR SPSS II program
(SPSS Japan Inc., Japan). We used the Mann–Whitney
U-test for unpaired non-parametric data and the Wilcoxon
signed-ranks test for continuous variables, as appropriate.
Similar comparisons of PT gland volume before and af-
ter treatment values within groups were done using the
Wilcoxon signed-ranks test. Logistic regression models
were applied to identify the factors that significantly affect
the prognosis of PT gland enlargement. A P-value <0.05
was considered significant.
Results
Clinical features
As shown in Table 1, both the DO group and the IV group
were similar with regard to age, gender, primary disease,
haemodialysis duration, history of vitamin D therapy and
dialysate calcium concentration. Concerning haematolog-
ical markers, we measured the levels of corrected cal-
cium, phosphate, alkaline phosphatase (ALP), intact PTH,
BAP, OC and N-telopeptide cross-linked of type I collagen
(NTX). There were no significant differences between the
two groups. As the sale of an OC-measuring kit was dis-
continued during the study period, OC was excluded from
the subsequent survey.
Changes in biochemical parameters
After administration, the serum-corrected Ca levels sig-
nificantly increased in the two groups (Figure 1A). There
were no changes in the serum Pi level in both groups
(Figure 1B). In the two groups, the intact PTH levels sig-
nificantly decreased after 1 month (Figure 1C). There were
no significant differences in any parameters between the
two groups. The total doses of VD during treatment were
91.5 ± 40.6 µg and 82.9 ± 31.2 µg in the DO and IV
groups, respectively, with no significant difference. There
were no differences in the doses of Ca carbonate and seve-
lamer administration between the two groups. No patient
took calcimimetics.
Parathyroid gland volume
There were no significant differences in the maximum PT
gland volume at the start of administration nor total volume
betweenthetwogroups(Table1).Weadditionallyevaluated
the PT volume 12 months after the start of administration
(Figure2).IntheDOgroup,themaximumPTglandvolume
significantly increased (49 ± 73 mm3 → 101 ± 141 mm3,
P = 0.007). In the IV group, there were no changes in the
volume (96 ± 215 mm3 → 89 ± 170 mm3). In the DO
group, the total volume also increased (65 ± 108 mm3 →
134 ± 196 mm3, P = 0.006). In the IV group, there was no
significant increase (150 ± 292 mm3 → 135 ± 250 mm3).
There was a significant difference in the change of the PT
volume between the two groups (Figure 3). The changes of
both maximum and total gland volume were significantly
larger in the DO group than those in the IV group (P =
0.047 and 0.015, respectively).
Examination of factors influencing parathyroid gland
enlargement
In this study, we investigated factors influencing PT gland
enlargement using a logistic regression model. Initially,
in our univariate logistic regression analysis, the serum-
corrected Ca and ALP levels were detected as factors in-
fluencing PT gland enlargement, as shown in Table 2 (P =
0.018 and 0.046, respectively). In particular, the odds ratio
of corrected Ca was extremely high (3.028). Our multivari-
ate analysis, in which the data were corrected with gender,
primary disease, history of VD therapy and dialysate Ca
concentrations, also showed that a higher serum-corrected
Ca level at the start of administration promoted PT en-
largement (Table 3). A study reported that FGF23 was a
prognostic factor for refractory hyperparathyroidism [17];
therefore,wealsoreviewedthisparameter.Inourunivariate
analysis, the P-value of log FGF23 was 0.051, showing no
significantdifference.However,thenumberofpatientswas
small, and we cannot rule out the possibility that FGF23 is
a prognostic factor for PT enlargement.Early IV calcitriol prevents PT growth 3665
Fig. 1. Changes in serum biochemical parameters following treatment with daily oral and intravenous calcitriol for 12 months. (A) Effects of calcitriol
therapy on serum-corrected calcium, (B) serum phosphate and (C) serum intact PTH concentrations. Calcitriol therapy was started at time zero. The
daily oral (DO) group is represented by the closed circle (), whereas the intravenous (IV) group is represented by the open circle (). Data are
expressed as mean ± SD. ∗P<0.05, ∗∗P<0.01 versus at time zero.
Changes in bone metabolism markers
Markers of bone metabolism were expressed as the rates
of change in BAP and NTX (Figure 4). In the DO group,
the BAP level significantly decreased 6 months or more
after the start of administration. However, there were no
changes in the IV group. In the DO group, the NTX level
significantly decreased 3 months or more after the start of
administration (P <0.01). In the IV group, it significantly
decreasedafter12monthsormore(P<0.05).However,the
decrease was less marked than that in the DO group.
Discussion
In this study, intravenous VD therapy in the early stage in-
hibited the deterioration of PT hyperplasia. There was no3666 M. Taniguchi et al.
Fig. 2. Maximum and total parathyroid gland volume before (white bar) and after treatment (grey bar) with daily oral and intravenous calcitriol. DO,
the daily oral group; IV , the intravenous group. Median values and interquartile ranges were given.
Fig. 3. Changes of maximum and total parathyroid gland volume during the treatment with daily oral and intravenous calcitriol. DO, the daily oral
group; IV , the intravenous group. Median values and interquartile ranges were given.
significant difference in the total dose of calcitriol during
the study period between the two groups; therefore, the dif-
ference in the administration method may have contributed
to the inhibition of PT enlargement. These results suggest
that intravenous VD therapy inhibits the deterioration from
diffuse hyperplasia to nodular hyperplasia, a clinical prob-
lem. When the condition reaches nodular hyperplasia, its
response to intravenous VD therapy is less marked due to
quantitative (an increase in the cell count) and qualitative
(decreases in the CaSR and VDR expressions) changes,
requiring PT intervention in many cases. In our previous
study regarding the PT gland after kidney transplantation,
kidney transplantation did not cause quantitative nor quali-
tative changes in the nodular hyperplasia, but induced both
quantitative (the enhancement of apoptosis) and qualita-
tive (increases in the CaSR and VDR expressions) changes
in the diffuse hyperplasia [18]. Briefly, these results sug-
gest that intravenous VD therapy in the early stage main-
tainsqualityandquantityindiffusehyperplasia,facilitating
long-term conservative therapy. It may have any effect on
thenodularhyperplasiaqualitatively/quantitatively.Anani-
malexperimentshowedthatthebolusadministrationofVD
in the early stage of renal failure inhibited PT hyperplasia,
suppressingadecreaseinVDR[15,19].Furthermore,intra-
venous VD therapy may maintain the expression of CaSR,
an aetiological factor for the medical treatment-refractory
condition [20,21,22]. In another study that we performed,
Ca/Pi control in patients with an intact PTH level of
>300 pg/ml at the start of intravenous VD therapy was
more difficult than in those with an intact PTH level of
<300 pg/ml. It was also impossible to administer a suffi-
cientdoseofVDforalongperiod,requiringPTintervention
inahighproportionofpatients(datanotshown).PoorCa/Pi
control may induce vascular calcification, leading to a poor
prognosis. In contrast, the start of intravenous VD therapy
in the phase of diffuse hyperplasia, in which the PTH level
is low, may reduce the risk of PT intervention and achieve
good Ca/Pi control, improving the prognosis.
Inthepresentstudy,thereweresomeimportantproblems.
Firstly, the target range of intact PTH level was compara-
bly low. There was some risk of developing adynamic bone
disease. In the K/DOQI guidelines [23], it is recommended
that the intact PTH level in patients undergoing dialysis
should be controlled to 150–300 pg/ml from the perspec-
tive of bone biopsy. When the intact PTH level exceeds
300 pg/ml, VD therapy, and if possible, intravenous VDEarly IV calcitriol prevents PT growth 3667
Table 2. Relative risk of parathyroid gland enlargement using univariate
logistic regression models (n = 60)
P-value Odds
ratio
95% confidence
interval
Age (every 1 year) 0.840
Gender (male/female) 0.266
Primary disease (DM/non-DM) 0.301
Haemodialysis duration (every
1 year)
0.224
History of vitamin D therapy
(yes/no)
0.380
Dialysate calcium (2.5/3.0 mEq/l) 0.449
Biochemical parameters at the
start
Corrected calcium (every
1 mg/dl)
0.018 3.028 1.214–7.552
Phosphate (every 1 mg/dl) 0.912
Alkaline phosphatase (every
1 U/l)
0.046 0.991 0.982–1.000
Intact PTH (every 1 pg/ml) 0.351
BAP (every 1 U/l) 0.185
OC (every 1 ng/ml) 0.650
NTX (every 1 nmol/l) 0.839
FGF23 (every 1 ng/l) 0.116
Log FGF23 0.051
DM, diabetes mellitus; PTH, parathyroid hormone; BAP, bone-specific
alkaline phosphatase; OC, osteocalcin; NTX, N-telopeptide cross-linked
of type 1 collagen.
therapy should be started. In Japan, the Japanese Society
of Dialysis and Transplantation (JSDT) published guide-
lines on secondary hyperparathyroidism in 2006 [24]. It is
recommended that the target intact PTH level should be
established as 60–180 pg/ml with respect to the prognosis.
In the adynamic bone disease, the reduced bone-buffer ca-
pacity would raise the serum levels of Ca and Pi, inducing
vascular calcification. However, the present study revealed
that both calcitriol therapies showed good Ca and Pi con-
trol (Ca × Pi product <55 mg2/dl2). This fact suggested
that the target range of PTH level should be influenced
by the prognosis. The second problem is the different ef-
fects to PT enlargement between daily, oral administration
and IV administration. This finding was in agreement with
Table 3. Relativeriskofparathyroidglandenlargementusingmultivariate
logistic regression models (n = 60)
P–value Odds ratio 95% confidence interval
Corrected calcium 0.017 3.662 1.260–10.644
(every 1 mg/dl)
Alkaline phosphatase 0.043 0.987 0.975–1.000
(every 1 U/l)
Adjusted for gender, primary kidney disease, history of vitamin D therapy
and dialysate calcium concentration.
previous studies [15], in which the prevention of PT en-
largement in partial nephrecomized rat is more effectively
suppressed when the same total dose of 1,25(OH)2D3 is
given by intermittent bolus administration than by continu-
ous infusion. The high peak serum levels of 1,25(OH)2D3
mightbeeffectiveforpreventingPTenlargement[25];how-
ever, our study did not address this issue. The third problem
is that the measurements of parathyroid gland size were
made by some examiners in various centres. The accuracy
of measurement might be unclear.
WeinvestigatedfactorsinvolvedinPTenlargementusing
univariate and multivariate analyses. The results suggested
theinvolvementoftheserumCaandALPlevelsatregistra-
tion.Inparticular,theformershowedahighoddsratio.This
may reflect a difference in the set point in the Ca–PTH re-
lation curve. Briefly, the PTH level was high despite a high
Ca level, suggesting that the condition had histologically
reached nodular hyperplasia. Concerning the ALP level,
the maintenance of the bone-buffer capacity may lead to
a good Ca control. This may allow VD therapy at an in-
creased dose, inhibiting PT enlargement. However, there
was no such correlation with the BAP level; therefore, we
cannot rule out the influence of liver dysfunction. Recently,
Nakanishi et al. [17] reported that the blood FGF23 level
was a prognostic factor for refractory hyperparathyroidism.
However, in this study, there was no correlation between
the blood FGF23 level and PT enlargement.
Previous studies have reviewed the actions of VD on
bones. Many studies have reported that intravenous VD
therapy relieved secondary hyperparathyroidism-related
Fig. 4. Changes in serum biochemical parameters following treatment with daily oral and intravenous calcitriol for 12 months. Effects of calcitriol
therapy on serum bone-specific alkaline phosphatase (BAP) and N-telopeptide cross-linked of type 1 collagen (NTX). Calcitriol therapy was started at
time zero. Data are expressed as mean ± SD. ∗P <0.05, ∗∗P <0.01 versus at time zero.3668 M. Taniguchi et al.
osteitis fibrosa [26,27,28]. However, it remains to be clar-
ified which of the two factors, the direct actions of VD
or a decrease in the PTH level, is involved in the action
mechanism. In this study, in the DO group, bone absorp-
tion and formation significantly reduced. In the IV group,
the bone formation marker was comparably constant, with
no decrease, in spite of a decrease in the PTH level. Several
in vitro studies indicated that VD enhanced ALP activity
directly [29,30,31,32]. These facts suggest that the differ-
ence of VD treatment method may affect bone metabolism
in vivo. However, we could not explain the discrepancy
between the effects on bone.
This study showed that intravenous VD therapy in the
early stage significantly inhibited the deterioration of PT
hyperplasia. Intravenous VD therapy in the phase of dif-
fuse hyperplasia may prevent the deterioration to nodular
hyperplasia, avoiding parathyroidectomy. In addition, good
control of the serum levels of PTH, Ca and Pi may in-
hibitvascularcalcification,improvingtheprognosis.When
echography shows PT enlargement in the presence of mild
secondary hyperparathyroidism, intravenous VD therapy
should be started in the early stage.
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